A randomized, placebo‐controlled trial of levetiracetam in central pain in multiple sclerosis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Levetiracetam is an anticonvulsant which is assumed to act by modulating neurotransmitter release via binding to the vesicle protein SV2A. This could have an impact on signalling in the pain pathway. The aim of this study was to test the analgesic effect of levetiracetam in central pain in multiple sclerosis. This was a randomized, double‐blind, placebo‐controlled, cross‐over trial with levetiracetam 3000 mg/day versus placebo (6‐week treatment periods). Patients with multiple sclerosis, symptoms and signs complying with central neuropathic pain and pain symptoms for more than 6 months, as well as pain intensity of more than 4 on a 0 to 10‐point numeric rating scale were included in the study. The primary outcome measure was pain relief at the end of each treatment period as measured on a 6‐point verbal scale. Eighty‐nine patients were screened for participation and 30 patients entered the study. Twenty‐seven patients were included in the data analysis. There were no differences in the ratings of pain relief (levetiracetam 2.4 vs. placebo 2.1, p = 0.169), total pain intensity (levetiracetam 5.3 vs. placebo 5.7, p = 0.147) or any of the other outcome measures (p = 0.086–0.715) in the total sample of patients. However, there was significant reduction of pain, increased pain relief and/or more favourable pain relief with levetiracetam than with placebo in patients with lancinating or without touch‐evoked pain (p = 0.025–0.046). This study found no effect of the anticonvulsant levetiracetam in non‐selected patients with central pain in multiple sclerosis, but an effect in subgroups with specific pain symptoms was indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610 · cited 1×
“It presumably modulates neurotransmitter release by binding to the vesicle protein called SV2A on presynaptic vesicles containing neurotransmitters (Lynch et al., 2004).”
BackgroundZajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679 · cited 1×
“Within the past decade, it has been reported that cannabinoids relieve this type of pain but with a rather modest efficacy (Zajicek et al., 2003; Svendsen et al., 2004; Rog et al., 2005).”
BackgroundSvendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500 · cited 1×
“Within the past decade, it has been reported that cannabinoids relieve this type of pain but with a rather modest efficacy (Zajicek et al., 2003; Svendsen et al., 2004; Rog et al., 2005).”
Background
Cited by
Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms
Jensen, T. S., & Finnerup, N. B. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70102-4 · Cited by 976
Levetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
“reported the beneficial effects of LEV (3000 mg/day for 6 weeks) in the control of central neuropathic pain symptoms in patients with multiple sclerosis (MS) [13,14].”
BackgroundShkodina, A. D., Bardhan, M., Chopra, H., Anyagwa, O. E., Pinchuk, V. A., Hryn, K. V., Kryvchun, A. M., Boiko, D. I., Suresh, V., Verma, A., et al. (2024) · CNS Drugs · doi:10.1007/s40263-024-01072-5 · Cited by 31
Metadata
- Authors
- Falah, M., Madsen, C., Holbech, J. V., & Sindrup, S. H.
- Venue
- European Journal of Pain
- Publisher
- Wiley
- Published
- 2011-12-19
- Volume
- 16
- Issue
- 6
- Pages
- 860-869
- ISSN
- 1090-3801 (ISSN-L)
- 1532-2149
- OpenAlex
- W1705148237
- Cited by
- 46
- References
- 4
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, placebo‐controlled trial of levetiracetam in central pain in multiple sclerosis. https://app.cochat.ai/papers/10.1002/j.1532-2149.2011.00073.x
- The paper
- Falah, M., Madsen, C., Holbech, J. V., & Sindrup, S. H. (2012). A randomized, placebo‐controlled trial of levetiracetam in central pain in multiple sclerosis. European Journal of Pain. https://doi.org/10.1002/j.1532-2149.2011.00073.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.